|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
PL3277321T3
(pl)
|
2015-04-01 |
2024-11-18 |
Anaptysbio, Inc. |
Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
|
|
MA43028B1
(fr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Anticorps bispécifiques pour pd1 et tim3
|
|
BR112018012352A2
(pt)
|
2015-12-16 |
2018-12-11 |
Merck Sharp & Dohme Corp. |
anticorpos anti-lag3 e fragmentos de ligação ao antígeno
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
MY190805A
(en)
|
2016-09-08 |
2022-05-12 |
Daiichi Sankyo Co Ltd |
Antibody for treating autoimmune diseases
|
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
US11390676B2
(en)
|
2016-10-13 |
2022-07-19 |
Symphogen A/S |
Anti-LAG-3 antibodies and compositions
|
|
CN110049777A
(zh)
|
2016-11-01 |
2019-07-23 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
|
MA50677A
(fr)
|
2016-11-01 |
2021-07-14 |
Anaptysbio Inc |
Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
|
|
PT3565844T
(pt)
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
AU2018205401B2
(en)
|
2017-01-09 |
2025-01-02 |
Tesaro, Inc. |
Methods of treating cancer with anti-TIM-3 antibodies
|
|
BR112019016336A2
(pt)
|
2017-02-10 |
2020-03-31 |
Regeneron Pharmaceuticals, Inc. |
Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
|
|
WO2018153340A1
(en)
*
|
2017-02-22 |
2018-08-30 |
I-Mab |
Anti-lag-3 antibodies and uses thereof
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
AU2018247916B2
(en)
*
|
2017-04-05 |
2025-04-24 |
Les Laboratoires Servier |
Combination therapies targeting PD-1, TIM-3, and LAG-3
|
|
CA3052532A1
(en)
|
2017-04-05 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
UA128387C2
(uk)
|
2017-04-05 |
2024-07-03 |
Ф. Хоффманн-Ля Рош Аг |
Антитіло до lag3
|
|
TWI791519B
(zh)
*
|
2017-04-27 |
2023-02-11 |
美商提薩羅有限公司 |
針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途
|
|
TW202444417A
(zh)
|
2017-05-09 |
2024-11-16 |
美商提薩羅有限公司 |
治療癌症的組合療法
|
|
CN110913911A
(zh)
|
2017-05-18 |
2020-03-24 |
特沙诺有限公司 |
用于治疗癌症的组合疗法
|
|
JP7301002B2
(ja)
|
2017-05-30 |
2023-06-30 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
|
|
WO2018222718A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
JP2020522495A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
|
|
JP2020536495A
(ja)
|
2017-08-30 |
2020-12-17 |
フェインズ セラピューティクス，インコーポレーテッド |
抗ｌａｇ−３抗体及びその使用
|
|
CN111278433A
(zh)
|
2017-09-26 |
2020-06-12 |
特沙诺有限公司 |
尼拉帕尼制剂
|
|
WO2019067978A1
(en)
|
2017-09-30 |
2019-04-04 |
Tesaro, Inc. |
POLYTHERAPIES FOR THE TREATMENT OF CANCER
|
|
US11801240B2
(en)
|
2017-10-06 |
2023-10-31 |
Tesaro, Inc. |
Combination therapies and uses thereof
|
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
|
|
JP7438180B2
(ja)
|
2018-03-20 |
2024-02-26 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗ｌａｇ－３抗体ポリペプチド
|
|
CN110305215B
(zh)
*
|
2018-03-20 |
2023-11-03 |
基石药业 |
新型抗lag-3抗体多肽
|
|
CN110343178B
(zh)
*
|
2018-04-03 |
2022-07-22 |
上海开拓者生物医药有限公司 |
抗人lag-3单克隆抗体及其应用
|
|
CN110615840A
(zh)
*
|
2018-06-19 |
2019-12-27 |
信达生物制药(苏州)有限公司 |
全人源的抗lag-3抗体及其应用
|
|
WO2020005003A1
(ko)
*
|
2018-06-29 |
2020-01-02 |
주식회사 와이바이오로직스 |
Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도
|
|
AU2019309849A1
(en)
|
2018-07-26 |
2021-03-18 |
Bristol-Myers Squibb Company |
LAG-3 combination therapy for the treatment of cancer
|
|
TWI852940B
(zh)
|
2018-09-04 |
2024-08-21 |
美商泰沙羅公司 |
治療癌症之方法
|
|
CN113166071B
(zh)
|
2018-10-03 |
2025-03-21 |
特沙诺有限公司 |
尼拉帕利盐
|
|
US12297184B2
(en)
|
2018-10-03 |
2025-05-13 |
Tesaro, Inc. |
Niraparib salts
|
|
WO2020081928A1
(en)
|
2018-10-19 |
2020-04-23 |
Bristol-Myers Squibb Company |
Combination therapy for melanoma
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
CN112010972B
(zh)
*
|
2019-05-31 |
2023-01-10 |
瑞阳(苏州)生物科技有限公司 |
与人lag-3蛋白结合的抗体及其编码基因和应用
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
WO2021055994A1
(en)
|
2019-09-22 |
2021-03-25 |
Bristol-Myers Squibb Company |
Quantitative spatial profiling for lag-3 antagonist therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
EP4054723A1
(en)
|
2019-11-08 |
2022-09-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
EP4077388A1
(en)
|
2019-12-18 |
2022-10-26 |
Tesaro, Inc. |
Biopharmaceutical compositions and related methods
|
|
WO2021146749A1
(en)
|
2020-01-13 |
2021-07-22 |
The University Of Chicago |
Toll-like receptor agonist formulations and methods of use
|
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
CN116234568A
(zh)
|
2020-07-07 |
2023-06-06 |
生物技术公司 |
用于hpv阳性癌症的治疗性rna
|
|
MX2023002332A
(es)
|
2020-08-28 |
2023-03-21 |
Bristol Myers Squibb Co |
Terapia con antagonistas del gen 3 de activacion de linfocitos (lag-3) para carcinoma hepatocelular.
|
|
IL300916A
(en)
|
2020-08-31 |
2023-04-01 |
Bristol Myers Squibb Co |
Cell localization signature and immunotherapy
|
|
CA3196496A1
(en)
|
2020-10-23 |
2022-04-28 |
Laurence David TOMS |
Lag-3 antagonist therapy for lung cancer
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
PT4267105T
(pt)
|
2020-12-28 |
2025-04-30 |
Bristol Myers Squibb Co |
Composições de anticorpos e métodos de utilização das mesmas
|
|
AU2021416156A1
(en)
|
2020-12-28 |
2023-06-22 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
|
CN112852870B
(zh)
*
|
2021-01-13 |
2022-03-04 |
北京鼎成肽源生物技术有限公司 |
IL-18基因融合H2Kk基因在制备增强细胞免疫的细胞中的应用、细胞及制备方法
|
|
EP4284950A4
(en)
|
2021-01-29 |
2024-12-25 |
Board of Regents, The University of Texas System |
METHODS OF TREATMENT OF CANCER USING KINASE INHIBITORS
|
|
CN114907478A
(zh)
*
|
2021-02-08 |
2022-08-16 |
迈威(上海)生物科技股份有限公司 |
结合lag-3的抗体及其用途
|
|
CN117858719A
(zh)
|
2021-03-29 |
2024-04-09 |
朱诺治疗学股份有限公司 |
使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
|
|
EP4319755A4
(en)
|
2021-04-08 |
2025-03-26 |
Board of Regents, The University of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
US20240285740A1
(en)
|
2021-05-12 |
2024-08-29 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
|
WO2023285552A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
CN113603779B
(zh)
*
|
2021-08-18 |
2023-06-02 |
深圳市元谷生物科技有限公司 |
一种结合人淋巴细胞活化基因3(lag-3)的抗体及其用途
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023077090A1
(en)
|
2021-10-29 |
2023-05-04 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hematological cancer
|
|
AU2023213937A1
(en)
|
2022-01-26 |
2024-07-18 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
|
KR20240153583A
(ko)
|
2022-02-25 |
2024-10-23 |
브리스톨-마이어스 스큅 컴퍼니 |
결장직장암종에 대한 병용 요법
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
CN119156403A
(zh)
|
2022-03-08 |
2024-12-17 |
阿伦蒂斯治疗股份公司 |
抗紧密连接蛋白-1抗体增加t细胞可用性的用途
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
CN114874324B
(zh)
*
|
2022-05-13 |
2023-02-03 |
苏州旭光科星抗体生物科技有限公司 |
一种检测可溶性lag-3蛋白含量的酶联免疫检测试剂盒及应用
|
|
AU2023281061A1
(en)
|
2022-06-02 |
2024-12-05 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
AU2023403103A1
(en)
|
2022-12-01 |
2025-07-10 |
Medimmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
|
JP2026501506A
(ja)
|
2022-12-14 |
2026-01-16 |
アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ |
Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
|
|
KR20250123912A
(ko)
|
2022-12-21 |
2025-08-18 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 병용 요법
|
|
EP4665410A1
(en)
|
2023-02-17 |
2025-12-24 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
CN121712571A
(zh)
|
2023-08-15 |
2026-03-20 |
百时美施贵宝公司 |
陶瓷羟基磷灰石色谱流通法
|
|
TW202535926A
(zh)
|
2023-10-30 |
2025-09-16 |
美商再生元醫藥公司 |
穩定抗體配製物
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2026033885A1
(en)
|
2024-08-08 |
2026-02-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
AR134560A1
(es)
|
2023-12-08 |
2026-01-28 |
Astellas Pharma Inc |
Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
CN122459678A
(zh)
|
2023-12-29 |
2026-07-24 |
百时美施贵宝公司 |
KRAS抑制剂与Treg耗竭剂的组合疗法
|
|
US12521446B2
(en)
|
2024-02-27 |
2026-01-13 |
Bristol-Myers Squibb Company |
Anti-CEACAM5 antibody drug conjugates
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025226695A1
(en)
|
2024-04-23 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|
|
CN118275703B
(zh)
*
|
2024-06-03 |
2024-08-23 |
军科正源（北京）药物研究有限责任公司 |
检测抗淋巴细胞激活基因3抗体药物中和抗体的方法
|
|
WO2026096695A1
(en)
|
2024-10-31 |
2026-05-07 |
Bristol-Myers Squibb Company |
Anti-fucosyl-gm1 antibody drug conjugates
|
|
US20260144885A1
(en)
|
2024-11-22 |
2026-05-28 |
Bristol-Myers Squibb Company |
Anti-lrrc15 antibodies and uses thereof
|
|
US20260144884A1
(en)
|
2024-11-22 |
2026-05-28 |
Bristol-Myers Squibb Company |
Anti-lrrc15 antibody drug conjugates
|